期刊文献+

益生菌治疗草酸钙结石的研究进展 被引量:6

Update on probiotics for the treatment of calcium oxalate stones
下载PDF
导出
摘要 肾结石是泌尿系统常见疾病之一,其中草酸钙结石最常见且复发率高。肠道草酸吸收增加使得尿草酸排泄增多是形成草酸钙结石的重要病理因素。目前发现具有降解草酸功能的肠道菌群有产甲酸草酸杆菌、粪肠球菌、大肠埃希菌、迟缓真杆菌、雷氏普罗威登斯菌、乳酸杆菌和双歧杆菌类等,其中,产甲酸草酸杆菌是人类发现的第一个专门降解草酸的专性厌氧菌,其余均为条件性降解草酸的肠道定植菌。产甲酸草酸杆菌主要有3种酶参与代谢草酸:草酸-甲酸反向转运体(Oxl T)、甲酰基辅酶A转移酶(Frc)、草酰辅酶A脱羧酶(Oxc)。动物研究已经证实,产甲酸草酸杆菌除了能直接降解肠道中的草酸,还能通过促进肠道草酸分泌来减少肠道内草酸的吸收,从而降低尿液草酸排泄量。本综述主要阐述益生菌治疗草酸钙结石的研究进展,以期为其进一步研究开发提供参考。 Urolithiasis is one of the common diseases in urinary system, among which calcium oxalate stone is the most common one with a high recurrence rate. An important pathological factor for the formation of calcium oxalate stone is the increased absorption of oxalate from intestine, which leads to a high urine oxalate concentration. Intestinal bacteria known to be able to degrade oxalate includes Oxalobacter formigenes, Enterococcus faecalis, Escherichia coli, Eubacterium lentum, Providencia rettgeri, Lactobacillus and Bifidobacterium species, etc. Among those, Oxalobacter formigenes is the first oxalate-degrading obligate anaerobe found in human, while the rest are just conditioned bacteria with the function to degrade intestinal oxalate. There are three kinds of enzymes in Oxalobacter formigenes involved in the metabolism of oxalate, namely oxalate-formate antiporter(Oxl T), formyl-Co A transferase(Frc) and oxalyl-Co A decarboxylase(Oxc). Animal experiments have verified that Oxalobacter formigenes could reduce intestinal oxalate absorption by promoting the secretion of oxalate and degradation as well, thus decrease the excretion of urine oxalate. The present review will focus on the research progress of probiotics treatment for the calcium oxalate stones so as to provide reference for further research and development.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2016年第8期694-698,共5页 Medical Journal of Chinese People's Liberation Army
基金 国家自然科学基金(81500533)~~
关键词 益生菌 尿路结石症 草酸钙 probiotics urolithiasis calcium oxalate
  • 相关文献

参考文献45

  • 1Scales CD, Smith AC, Hanley JM, et al. Prevalence of kidney stones in the United States[Jl. Eur Urol, 2012, 62(1): 160-165.
  • 2Krepinsky J, Ingram AJ, Churchill DN. Metabolic investigation of recurrent nephrolithiasis: compliance with recommendations [J]. Urology, 2000, 56(6): 915-920.
  • 3Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline[J]. Ann Intern Med, 2013, 158(7): 535-543.
  • 4Fernando D, Adelaide S. Nephrolithiasis is associated with an increased prevalence of cardiovascular disease[J]. Nephrol Dial Transplant, 2011, 26(3): 864-868.
  • 5Sakhaee K, Capolongo G, Maalouf NM, et al. Metabolic syndrome and the risk of calcium stones[J]. Nephrol Dial Transplant, 2012, 27(8): 3201-3209.
  • 6Cho ST,Jung SI, Myung SC, et al. Correlation of metabolic syndrome with urinary stone composition[J]. Int J Urol, 2013, 20(2): 208-213.
  • 7Kabeya Y, Kato K, Tomita M, et al. Associations of insulin resistance and glycemic control with the risk of kidney stones [J]. Intern Med, 2012, 51(7): 699-705.
  • 8Worcester E, Parks JH, Josephson MA, et al. Causes and consequences of kidney loss in patients with nephrolithiasis [J]. Kidney Int, 2003, 64(6) : 2204-2213.
  • 9Jungers P, Joly D, Barbey F, et al. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention [J]. Am J Kidney Dis, 2004, 44(5): 799-805.
  • 10Lieske JC, Tremaine wJ, Claudio DS, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation[J]. Kideny Int, 2010, 78(11): 1178-1185.

二级参考文献11

  • 1Belostotsky R, Seboun E, Idelson GH, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type 1[J] [ J]. Am J Hmn Genet,2010,87 (3) :392 - 399.
  • 2Zhmlg X, Roe SM, Pearl LH, et al. Crystallization and preliminary crystallographic analysis of human alanine: glyoxylate aminotrans- ferase and its polymorphic variants [ J ]. Acta Crystallogr D Biol Crystallogr ,200l ,57 ( Pt 12 ) : 1936 - 1937.
  • 3Coulter-Mackie MB, Rumsby G. Geneticheterogeneityin primmy hy- peroxaluria type 1 : impact on diagnosis [ J ]. Mol Genet Metab, 2004,83(1 -2) :38 -46.
  • 4Monico CG, Rossetti S, Schwanz HA, et al. Comprehensivemutation- screeningin 55 probands with type 1 primary hyperoxaluria shows feasibility of a gene-based diagnosis [ J]. J Am Soc Nephrol,2007, 18(6) : 1905 - 1914.
  • 5Williams EL, Aequaviva C, Amoroso A. et al. Primary hyperoxaluria type 1 :update and additional mutation analysis of the AGXT gene [ R]. Hum Mutat,2009,30(6) :910 -917.
  • 6Pirulli D, Marangella M, Amoroso A. Primary hyperoxaluria: geno- type-phenotype colTelation [ J ]. J Nephrol,2003 ,16 :297 - 309.
  • 7Hori T,Egawa H, Kaido T, et al. Liver Transplantation for Primary Hyperoxaluria Type 1 :A Single-center Experience during Two Dec- ades in Japan [ J ]. World J Surg ,2013,37 (3) :688 -693.
  • 8Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1 : strat- egy for organ transplantation [ J ]. Curt Opin Organ Transplant, 2010,15(5) :590,593.
  • 9Makita [J], Yamakuma M, Matsumura T, et al. 14emodialysispatient regarded as a primary hyperoxaluria after long-term hemodialysis and renal transplantation [ J ]. Fukuoka Igaku Zasshi, 1995,86 ( 4 ) : 121 - 125.
  • 10Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria type 1 : indications for screening and guidance for diagnosis and treatment [J]. Nephrol Dial Transplant,2012,27(5) :1729 - 1736.

共引文献3

同被引文献61

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部